Related references
Note: Only part of the references are listed.Effect of intrapulmonary tetrahydrocannabinol administration in humans
L. Zuurman et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model
P. Jacqmin et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Dopamine challenge tests as an indicator of psychological traits
P Netter
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2006)
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo
DM Jonker et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence
B Le Foll et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Cannabinoid physiology and pharmacology: 30 years of progress
AC Howlett et al.
NEUROPHARMACOLOGY (2004)
Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients
JP van der Post et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2004)
Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle
A Bonz et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen
CLINICAL PHARMACOKINETICS (2003)
Cardiovascular effects of cannabinoids
MD Randall et al.
PHARMACOLOGY & THERAPEUTICS (2002)
The effects of tryptophan depletion on mood and psychiatric symptoms
AJW Van der Does
JOURNAL OF AFFECTIVE DISORDERS (2001)
Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716
MA Huestis et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
CB1 receptor-C protein association -: Subtype selectivity is determined by distinct intracellular domains
S Mukhopadhyay et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Share Paper
